Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  O'Byrne, Kenneth J ^a   Edwards, John G ^b   Waller, David A ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cyclooxygenase (COX) 2; Epidermal growth factor receptor expression; Matrix metalloproteinases; Prognostic factor; Tumour necrosis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; ROFECOXIB; TUMOR NECROSIS FACTOR RECEPTOR;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS;

CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; MESOTHELIOMA; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 3142752597     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.025     Document Type: Conference Paper

References (11)

1. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia Group B. Chest. 113:1998;723-731
2. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 16:1998;145-152
3. Edwards J.G., Abrams K.R., Leverment J.N., Spyt T.J., Waller D.A., O'Byrne K.J. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 55:2000;731-735
4. Kessler R., Gasser B., Massard G., Roeslin N., Meyer P., Wihlm J.M., et al. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg. 62:1996;1489-1493
5. Leek R.D., Landers R.J., Harris A.L., Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 79:1999;991-995
6. Edwards J.G., Cox G., Andi A., Jones J.L., Walker R.A., Waller D.A., et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer. 85:2001;863-868
7. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 61:1990;924-926
8. Edwards J.G., Faux S.P., Plummer S.M., Abrams K.R., Walker R.A., Waller D.A., et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res. 8:2002;1857-1862
9. Cox G., O'Byrne K.J. Matrix metalloproteinases and cancer. Anticancer Res. 21:2001;4207-4219
10. Edwards J.G., McLaren J., Jones J.L., Waller D.A., O'Byrne K.J. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 88:2003;1553-1559
11. Macaulay V.M., O'Byrne K.J., Saunders M.P., Braybrooke J.P., Long L., Gleeson F., et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 5:1999;513-520